EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Amentoflavone and cancer: mechanistic insights and translational perspectives

Hiroki Hashida, Atsushi Kobayashi, Masatoshi Akagami, Tomohiro Okamoto, Hirokazu Tanaka

Frontiers in Oncology · 30.07.2026 · 16

DOI: 10.3389/fonc.2026.1813172 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 30.07.2026. Verfasst von Hiroki Hashida und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Hanwa Memorial Hospital, Osaka, Japan. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amentoflavone (AF) is a naturally occurring biflavonoid isolated from multiple medicinal plants and widely studied for anti-inflammatory and antioxidant activities. In oncology, AF has emerged as a pleiotropic small molecule that modulates interconnected signaling axes rather than a single node. Preclinical studies indicate that AF attenuates PI3K/Akt/mTOR signaling and NF-κB–dependent survival programs, disrupts Wnt/β-catenin–linked epithelial–mesenchymal transition (EMT), and modulates MAPK cascades to promote apoptosis and cell-cycle arrest. AF also interferes with pro-angiogenic signaling and VEGF-driven neovascularization. Across diverse cancer models, these activities translate into reduced proliferation, enhanced apoptosis, suppression of invasion/EMT, and inhibition of tumor-associated angiogenesis. However, translation remains limited by poor aqueous solubility, low oral exposure, and incomplete exposure–response and safety characterization. Recent drug delivery approaches (polymeric micelles, mixed nanomicelles, DSPE-PEG micelles) and rational combination strategies provide practical routes to improve systemic exposure and revisit AF in combination regimens. This review integrates mechanistic and tumor-specific evidence with a clear distinction between direct target binding and downstream pathway readouts, quantitative in vitro / in vivo endpoints, an expanded reference list using verifiable sources, and priorities for pharmacokinetic optimization, toxicity evaluation, and biomarker-guided early-phase development.

Schlagwörter

Stichwörter der Autor:innen

EMTNF-κBamentoflavoneangiogenesisapoptosisbiflavonoidformulationpharmacokinetics

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, Hanwa Memorial Hospital, Osaka, Japan.

Zitieren

APA

Hashida, H., Kobayashi, A., Akagami, M., Okamoto, T., & Tanaka, H. (2026). Amentoflavone and cancer: mechanistic insights and translational perspectives. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1813172

Vancouver

Hashida H, Kobayashi A, Akagami M, Okamoto T, Tanaka H. Amentoflavone and cancer: mechanistic insights and translational perspectives. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1813172

BibTeX
@article{Hashida2026,
  author = {Hashida, Hiroki and Kobayashi, Atsushi and Akagami, Masatoshi and Okamoto, Tomohiro and Tanaka, Hirokazu},
  title = {Amentoflavone and cancer: mechanistic insights and translational perspectives},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1813172}
}
Kostenlos starten →